Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002892|
Recruitment Status : Completed
First Posted : May 13, 2004
Last Update Posted : December 19, 2013
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known whether interferon alfa following surgery is more effective than surgery alone in treating patients with melanoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with no further therapy following surgery in treating patients with stage II, stage III, or recurrent melanoma.
|Condition or disease||Intervention/treatment||Phase|
|Melanoma (Skin)||Biological: recombinant interferon alfa||Phase 3|
OBJECTIVES: I. Determine the effects of adjuvant low-dose extended-duration interferon alfa on disease-free and overall survival in patients with completely resected malignant melanoma at high risk of recurrence. II. Determine any correlation between patient age or sex and the effects of interferon therapy on disease-free and overall survival. III. Describe the toxic effects of this treatment. IV. Evaluate the economic implications of implementing effective interferon therapy in these patients.
OUTLINE: This is a randomized study. Patients will be stratified by age, sex, disease status at entry, and participating institution. Patients are randomized to observation only or to receive interferon alfa by subcutaneous injections 3 times weekly for 2 years, or until disease progression or toxicity intervenes. Patients are followed monthly for 6 months, quarterly for 18 months, and every 6 months thereafter.
PROJECTED ACCRUAL: A total of 1,000 patients will be entered over 5 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1000 participants|
|Official Title:||A RANDOMISED STUDY OF OBSERVATION VERSUS ADJUVANT LOW DOSE EXTENDED DURATION INTERFERON ALPHA-2A IN COMPLETELY RESECTED HIGH RISK MALIGNANT MELANOMA|
|Study Start Date :||October 1995|
|Study Completion Date :||December 2001|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002892
|Royal Free Hospital|
|Hampstead, London, England, United Kingdom, NW3 2QG|
|St. James's Hospital|
|Leeds, England, United Kingdom, LS9 7TF|
|University Hospitals of Leicester|
|Leicester, England, United Kingdom, LE1 5WW|
|Guy's, King's and St. Thomas' Hospitals Trust|
|London, England, United Kingdom, SE1 7EH|
|Royal Marsden NHS Trust|
|London, England, United Kingdom, SW3 6JJ|
|Christie Hospital N.H.S. Trust|
|Manchester, England, United Kingdom, M20 4BX|
|Clatterbridge Centre for Oncology NHS Trust|
|Merseyside, England, United Kingdom, L63 4JY|
|Weston Park Hospital|
|Sheffield, England, United Kingdom, S1O 2SJ|
|Aberdeen Royal Infirmary|
|Aberdeen, Scotland, United Kingdom, AB25 2ZN|
|Selly Oak Hospital|
|Birmingham, United Kingdom, B29 6JD|
|Royal Bournemouth Hospital|
|Bournemouth, United Kingdom, BH7 7DW|
|Queen Elizabeth Hospital|
|King's Lynn, United Kingdom, PE30 4ET|
|Salisbury District Hospital|
|Salisbury, United Kingdom, SP2 8BJ|
|Southend on Sea, United Kingdom, SS0 0RY|
|Study Chair:||Barry W. Hancock, MD||Cancer Research Centre at Weston Park Hospital|